Publications by authors named "Gianpaolo Marcacci"

Claim this Profile
A
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies.
Danilo De Novellis, Salvatore Palmieri, Stefano Rocco, Daniele Derudas, Roberta Della Pepa, Gianpaolo Marcacci

Ann Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.
Danilo De Novellis, Daniele Derudas, Donatella Vincelli, Raffaele Fontana, Roberta Della Pepa, Gianpaolo Marcacci

Eur J Haematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with multiple myeloma infected with COVID-19 during autologous stem cell transplantation.
Rosaria De Filippi, Gianpaolo Marcacci, Sabrina Amelio, Cristina Becchimanzi, Antonio Pinto

Infect Agent Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study.
Rosaria De Filippi, Gianpaolo Marcacci, Enrico Derenzini, Maurizio Musso, Daniela Donnarumma

Cancers (Basel)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Antonella Bruzzese, Daniele Derudas, Monica Galli, Enrica Antonia Martino, Stefano Rocco, Gianpaolo Marcacci

Hematol Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation.
Gianpaolo Marcacci, Nicola Coppola, Emanuela Madonna, Cristina Becchimanzi, Stefania De Pascalis

Infect Agent Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.
Gianpaolo Marcacci, Giuseppe Fiorentino, Francesco Volzone, Umberto Falcone, Roberto Parrella

Infect Agent Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Massimo Gentile, Giorgina Specchia, Daniele Derudas, Monica Galli, Cirino Botta, Gianpaolo Marcacci

Haematologica· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Maurizio Musso, Giuseppe Messina, Nicola Di Renzo, Paolo Di Carlo, Umberto Vitolo, Gianpaolo Marcacci

Br J Haematol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Maurizio Musso, Giuseppe Messina, Gianpaolo Marcacci, Alessandra Crescimanno, Giuseppe Console

Biol Blood Marrow Transplant· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of allogeneic platelet gel in the management of chemotherapy extravasation injuries: a case report.
Gaetano Di Costanzo, Giovanna Loquercio, Gianpaolo Marcacci, Vincenzo Iervolino, Stefano Mori

Onco Targets Ther· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
Filippo Russo, Gaetano Corazzelli, Ferdinando Frigeri, Gaetana Capobianco, Luigi Aloj, Gianpaolo Marcacci

Br J Haematol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.
Gaetano Corazzelli, Ferdinando Frigeri, Manuela Arcamone, Luigi Aloj, Gaetana Capobianco, Gianpaolo Marcacci

Eur J Haematol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy.
Gaetano Corazzelli, Ferdinando Frigeri, Manuela Arcamone, Anna Lucania, Maria Rosariavilla, Gianpaolo Marcacci

Br J Haematol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma.
Gaetano Corazzelli, Rosaria De Filippi, Gaetana Capobianco, Ferdinando Frigeri, Vincenzo De Rosa, Gianpaolo Marcacci

Am J Hematol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
Gaetano Corazzelli, Gaetana Capobianco, Manuela Arcamone, Pier Ferruccio Ballerini, Emilio Iannitto, Gianpaolo Marcacci

Cancer Chemother Pharmacol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
Giovanni D'Arena, Luca Laurenti, Silvana Capalbo, Alfonso Maria D'Arco, Rosaria De Filippi, Gianpaolo Marcacci

Am J Hematol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis